Lancet neurology: The safety and effectiveness of Pernisson in the short-term prevention of seizure congeal headaches

Cluster headache (cluster headache, CH) is one of the vascular headaches.
is characterized by intensive seizures over a period of time and is therefore one of the more severe of all headaches.
CH is more common in young people, 20 to 40 years old, male incidence rate is 4 to 5 times that of women, generally no family history.
is different from migraines, ch attacks before no precursor, headache fixed around one side of the eye and eye socket.
seizures mostly in the evening, the initial feeling of one side of the eye and the eye socket around the feeling of swelling or compression, after a few minutes rapid development into severe swelling pain or drilling pain, and spread to the same side of the forehead and pillow, accompanied by pain side conjunctivation, tears, runny nose, sweating, eyelids mild edema, little vomiting.
patients with headache attack is very painful, sitting restless, generally lasts 15 to 180 minutes, after which the symptoms quickly disappear, after remission can still engage in the original activities.
occurs when there is a congeal seizure, i.e. 1 to several times a day, at about the same time every day, some like a fixed clock, almost at a constant time, the symptoms and duration of each episode is almost the same.
usually used for the initial short-term treatment of occasional CH before the preventive drug Virrapami, etc. came into effect.
there are no large randomized trials to verify its effectiveness.
this, a team of experts from the Department of Neurology at the University Hospital of Essen in Germany conducted a multi-center randomized double-blind trial of the efficacy of Pernieson's treatment of CH, the results of which were published in the journal Lancet Neurology.
the study recruited CH patients between the ages of 18 and 65 from 10 German specialist headache centres with headaches of up to 30 days.
all patients were treated with oral verapami for long-term prevention, and then the interactive network was used to randomly divide the strong pine group (100 mg orally for 5 days, gradually reducing the amount by 20 mg every 3 days) with the placebo group.
of the study was the number of headache attacks in the first week of the treatment compared to the placebo group.
the attack is defined as a numeric scale above 5 points.
treatment intent analysis (mITT) to evaluate the efficacy and safety analysis.
2013.04.05-2018.01.11, a total of 116 patients were randomly grouped (57 in the Pernisson group and 59 in the placebo group) and 109 were included in the mITT analysis.
average number of seizures in the first week of the Ponieson group and the control group was 7.1 VS 9.5 (difference -2.4, 95% CI-4.8-0.03, p-0.002).
two serious adverse events (severe deterioration of groin palate and CH) occurred in the placebo group in the study.
addition, adverse events included headache, palpitations, dizziness and nausea, with 270 cases occurring, of which 135 were reported in 37 patients (71%) in the pernissosis group and 135 in the placebo group of 55 (71%).
number of headaches per day in both groups of patients.
, oral pernisone is an effective short-term method of preventing CH seizures.
long-term preventive effects of ernisson still need further study.
references: Obermann M, Nägel S, Ose C, et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. Lancet Neurol. 2021 Jan; 20(1):29-37. doi: 10.1016/S1474-4422 (20) 30363-X.MedSci Original Source: MedSci Original Copyright Notice: All noted on this website "Source: May The text, images and audio-visual materials of SMM or Source: MedSci Originals are owned by Mace Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Metz Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here